Updated OS and PFS: What 32 Months of Follow-up Confirms
The updated DESTINY-Breast04 analysis, with a median follow-up of 32.0 months, confirms a sustained and clinically meaningful survival benefit for trastuzumab deruxtecan (T-DXd) over treatment of physician’s choice (TPC) in HER2-low metastatic breast cancer. The long-term data do not modify the primary conclusions — they strengthen them.
In the overall cohort, median OS was 22.9 months for T-DXd versus 16.8 months for TPC (HR 0.69; 95% CI 0.55–0.86), representing a 31% reduction in the risk of death. In the hormone receptor-positive (HR+) cohort, median OS was 23.9 months for T-DXd versus 17.6 months for TPC (HR 0.69; 95% CI 0.55–0.87) — again a 31% reduction. In the exploratory HR-negative cohort, T-DXd demonstrated a 42% reduction in the risk of death.
Progression-free survival results were equally compelling. Median PFS by investigator assessment was 8.8 months for T-DXd versus 4.2 months for TPC in the overall cohort (HR 0.36; 95% CI 0.29–0.45). For the HR+ cohort, median PFS was 9.6 months for T-DXd versus 4.2 months for TPC (HR 0.37; 95% CI 0.30–0.46). Importantly, the investigator-assessed PFS in this updated analysis showed similarity with the blinded independent central review (BICR) PFS from the primary analysis, supporting the conclusion that T-DXd’s activity is sustained with longer follow-up.
In the DESTINY-Breast04 trial at a median follow-up of 32.0 months, trastuzumab deruxtecan (T-DXd) achieved a median overall survival of 22.9 months versus 16.8 months for treatment of physician’s choice in the overall HER2-low metastatic breast cancer cohort (HR 0.69; 95% CI 0.55–0.86), confirming a 31% reduction in the risk of death.
These long-term results solidify T-DXd’s role as a standard of care for HER2-low metastatic breast cancer after prior chemotherapy, as affirmed by the DESTINY-Breast04 investigators. The updated analysis produced no meaningful modifications to the primary conclusions — rather, the durability of both OS and PFS benefits across the full follow-up period provides additional confidence in the original findings.
ER-Low-Positive Subgroup Findings and ASCO/CAP Classification Implications
T-DXd demonstrates clinically meaningful benefit in patients with ER-low-positive tumors (IHC 1%–10%), a subgroup whose optimal treatment has been uncertain under current classification frameworks. The DESTINY-Breast04 exploratory data provide the most robust evidence to date for this population.
In the ER-low-positive subgroup, T-DXd achieved a median OS of 22.3 months versus 10.2 months for TPC (HR 0.40; 95% CI 0.20–0.79) — a 60% reduction in the risk of death. Median PFS was 8.3 months for T-DXd versus 2.3 months for TPC (HR 0.27; 95% CI 0.14–0.52). These outcomes are comparable to those observed in the ER >10% subgroup, suggesting that T-DXd’s efficacy is largely independent of the ER level in the tumor.
The ASCO/CAP guidelines introduced a reporting category for breast cancers with 1%–10% ER tumor nuclei staining. These patients often have a similar response to cancer treatment as hormone receptor-negative breast cancer and are unlikely to benefit from endocrine therapy, making optimal systemic treatment selection a clinical challenge.
The clinical significance of this finding is substantial. According to ASCO‘s updated guidelines, the ER-low-positive category was introduced precisely because these patients frequently behave more like HR-negative disease and derive limited benefit from endocrine therapy. The DESTINY-Breast04 data validate this classification by demonstrating that T-DXd — rather than endocrine-based strategies — provides substantial survival benefit to this subgroup, with an OS hazard ratio of 0.40 that numerically exceeds the benefit seen in the broader HR+ population.
“In the ER-low-positive subgroup, T-DXd achieved a median OS of 22.3 months versus 10.2 months for TPC — a hazard ratio of 0.40 — suggesting T-DXd’s efficacy is largely independent of ER level in the tumor.”
In the DESTINY-Breast04 exploratory ER-low-positive subgroup (IHC 1%–10%), trastuzumab deruxtecan (T-DXd) achieved a median overall survival of 22.3 months versus 10.2 months for treatment of physician’s choice (HR 0.40; 95% CI 0.20–0.79) and a median PFS of 8.3 months versus 2.3 months for TPC (HR 0.27; 95% CI 0.14–0.52).
These findings carry direct implications for how oncologists should approach patients with ER-low-positive, HER2-low metastatic breast cancer. Rather than defaulting to endocrine-based regimens — which are unlikely to provide meaningful benefit — clinicians now have evidence to support T-DXd as a preferred option for this subgroup. The data further validate the need for refined ER classification, as distinguishing ER-low-positive from both fully HR-positive and HR-negative disease enables more precise treatment selection guided by biomarker-stratified evidence.
Explore the full patent and clinical landscape for HER2-low ADC therapies with PatSnap Eureka.
Search HER2-Low ADC Patents in PatSnap Eureka →How Response Depth Predicts Long-Term Survival
Patients who achieve a complete response (CR) or partial response (PR) to T-DXd experience substantially more pronounced survival outcomes than non-responders, particularly for PFS — a finding with direct implications for how early response data might inform ongoing treatment decisions.
The exploratory efficacy analysis based on best confirmed response to T-DXd in DESTINY-Breast04 reveals a clear gradient. Patients achieving a CR (n=8) had a median PFS of 25.3 months (95% CI 6.9 to not estimable) and an OS that had not been reached (95% CI 20.3 to not estimable). Patients with a PR (n=188) had a median PFS of 11.1 months (95% CI 9.7–12.6) and an OS of 24.7 months (95% CI 23.0–30.4). These results are consistent with pooled analyses from DESTINY-Breast01, -02, and -03 trials in HER2-positive metastatic breast cancer, which similarly showed better OS and PFS for responders.
The clinical implication is that achieving a deep response to T-DXd is a strong prognostic indicator for improved long-term OS and PFS. While the DESTINY-Breast04 data do not explicitly establish formal early response-guided treatment decision protocols, the correlation between response depth and survival outcomes suggests that monitoring response to T-DXd could inform subsequent treatment strategies. Further prospective research would be required to establish evidence-based guidelines for response-adapted treatment decisions in this setting.
In DESTINY-Breast04, patients achieving CR or PR to T-DXd had more pronounced survival outcomes — especially for PFS — than non-responders. This pattern is consistent with pooled analyses from DESTINY-Breast01, -02, and -03 in HER2-positive metastatic breast cancer, suggesting response depth is a reproducible prognostic marker across the HER2 spectrum.
No Cumulative ILD: What Extended Follow-up Means for Long-Term T-DXd Use
After approximately 14 additional months of follow-up beyond the primary DESTINY-Breast04 analysis, no new cases of interstitial lung disease (ILD) and/or pneumonitis were reported — a finding with significant implications for how clinicians can approach long-term T-DXd treatment planning.
The adjudicated drug-related ILD/pneumonitis rate remained at 12.1% in the T-DXd arm across the extended follow-up period. This stability indicates that late-onset ILD is uncommon with T-DXd and that the drug does not lead to cumulative ILD toxicity over extended treatment durations. As noted by clinical bodies including ESMO, proactive monitoring and early management of ILD remain essential components of T-DXd treatment protocols.
In the DESTINY-Breast04 updated analysis with approximately 14 additional months of follow-up beyond the primary analysis, no new cases of ILD and/or pneumonitis were reported, and the adjudicated drug-related ILD/pneumonitis rate remained unchanged at 12.1% in the T-DXd arm, indicating that trastuzumab deruxtecan does not produce cumulative ILD toxicity with extended treatment.
The absence of cumulative ILD toxicity is clinically reassuring for several reasons. First, it allows oncologists to consider sustained T-DXd treatment in patients who are deriving benefit, without the concern that continued therapy will incrementally increase pulmonary toxicity risk. Second, it suggests that patients who have tolerated T-DXd through the early months of treatment — when ILD events are most likely to occur — are unlikely to develop new ILD events with continued therapy. Third, it reinforces the value of the proactive monitoring and management protocols recommended in published guidelines, which appear effective at identifying and treating ILD/pneumonitis early.
Analyse the ILD safety landscape across HER2-directed ADCs using PatSnap Eureka’s clinical intelligence tools.
Explore ADC Safety Data in PatSnap Eureka →The long-term ILD data from DESTINY-Breast04 provide a meaningful safety anchor for T-DXd’s expanding indications. As the drug is studied in earlier lines of therapy and in new patient populations — including HER2-ultralow disease — the absence of a cumulative ILD signal supports its feasibility for longer treatment courses. Regulatory guidance from bodies such as the FDA continues to evolve alongside these emerging safety datasets, with ILD monitoring requirements remaining a standard feature of T-DXd prescribing information.
T-DXd’s Position Across the Full HER2-Directed ADC Ecosystem
DESTINY-Breast04’s final results, combined with data from the DESTINY-Breast01, -02, -03, and -06 trials as well as the DAISY trial, position trastuzumab deruxtecan as the cornerstone HER2-directed antibody-drug conjugate (ADC) across the full spectrum of HER2 expression — from HER2-positive through HER2-low to HER2-ultralow disease.
HER2-Positive: Established Efficacy
Pooled analyses from DESTINY-Breast01, -02, and -03 have demonstrated T-DXd’s robust efficacy in HER2-positive metastatic breast cancer, establishing its role in the HER2-positive setting. These trials collectively confirmed that responders — those achieving CR or PR — had better OS and PFS outcomes, a pattern that is now reproduced in the HER2-low setting by DESTINY-Breast04.
HER2-Low: Standard of Care
DESTINY-Breast04 was pivotal in defining HER2-low (IHC 1+ or IHC 2+/ISH-negative) as a clinically targetable population. The trial established T-DXd as the standard of care for HER2-low metastatic breast cancer after prior chemotherapy, fundamentally reshaping the treatment algorithm for a population that had previously lacked a HER2-directed therapeutic option. According to data tracked by ClinicalTrials.gov, DESTINY-Breast04 remains one of the most cited trials in the contemporary ADC landscape.
HER2-Ultralow: An Expanding Frontier
DESTINY-Breast06 extended T-DXd’s reach to HER2-ultralow breast cancer, demonstrating significant PFS improvement in HR+, HER2-low, and HER2-ultralow patients after endocrine therapy but before chemotherapy. The DAISY trial additionally observed antitumor activity in HER2 IHC 0 metastatic breast cancer, suggesting that T-DXd’s activity may extend beyond traditional HER2-positive and HER2-low definitions — potentially through HER2-independent mechanisms of ADC uptake and efficacy.
The DESTINY-Breast06 trial demonstrated significant progression-free survival improvement with trastuzumab deruxtecan (T-DXd) in HR+, HER2-low, and HER2-ultralow patients after endocrine therapy but before chemotherapy, while the DAISY trial observed antitumor activity in HER2 IHC 0 metastatic breast cancer — collectively extending T-DXd’s clinical reach across the full HER2 expression spectrum.
The treatment landscape for HER2-low and HER2-ultralow breast cancer continues to expand, and the DESTINY-Breast04 investigators acknowledge the need for further assay optimisation and training for HER2 IHC 0 and HER2-ultralow scoring to ensure optimal treatment selection. As standardisation of HER2 testing evolves — guided by bodies such as CAP — the ability to accurately identify patients across the full HER2 expression spectrum will become increasingly critical to realising the full clinical benefit of T-DXd and next-generation HER2-directed ADCs.
“From HER2-positive to HER2-low to HER2-ultralow, trastuzumab deruxtecan now spans the entire HER2 expression spectrum — fundamentally reshaping the metastatic breast cancer treatment algorithm.”
Within the broader HER2-directed ADC ecosystem, DESTINY-Breast04’s long-term results reinforce T-DXd’s differentiated position. The combination of sustained OS and PFS benefit, no cumulative ILD toxicity, efficacy in ER-low-positive tumors, and activity across multiple HER2 expression categories makes T-DXd a uniquely versatile agent. As the field continues to investigate optimal sequencing, combination strategies, and biomarker-driven patient selection, the DESTINY-Breast04 dataset provides an essential long-term evidence base. Researchers and IP professionals tracking this space can access the full patent and clinical data landscape through PatSnap’s life sciences intelligence platform.